autophagi
import
mechan
tumor
escap
allow
tumor
cell
recov
damag
induc
chemotherapi
radiat
therapi
immunotherapi
contribut
develop
resist
pharmacolog
inhibit
autophagi
contribut
increas
efficaci
antineoplast
agent
expos
tumor
cell
low
concentr
select
autophagyinduc
antineoplast
agent
increas
immunogen
enhanc
abil
stimul
dendrit
cell
dc
matur
test
whether
applic
autophagyinhibit
agent
chloroquin
cq
combin
low
concentr
increas
abil
tumor
cell
induc
dc
matur
dc
sensit
lysat
cell
previous
expos
combin
enhanc
dc
maturationactiv
abil
matur
dc
also
increas
allogen
respons
cell
show
greater
prolif
respons
dc
sensit
control
lysat
cell
expand
cocultur
produc
higher
level
lower
level
consist
preferenti
activ
cell
cocultur
autolog
dc
lymphocyt
improv
gener
cytotox
lymphocyt
assess
express
perforin
granzym
b
drug
combin
increas
express
gene
relat
ceacam
famili
atg
tumor
suppressor
furthermor
decreas
express
gene
relat
metastasi
tumor
progress
note
combin
cq
increas
abil
tumor
cell
drive
dc
matur
enhanc
abil
dc
stimul
cell
respons
colorect
cancer
crc
third
frequent
cancer
observ
worldwid
new
case
expect
brazil
convent
therapi
patient
crc
base
total
partial
colectomi
usual
follow
neoadjuv
adjuv
chemotherapi
fluoropyrimidin
oxaliplatin
irinotecan
andor
taxan
success
chemotherapi
often
complic
metastas
relaps
diseas
associ
develop
drug
resist
one
mechan
respons
drug
resist
autophagi
select
cellular
degrad
process
cytosol
protein
organel
sequest
doublemembran
autophagosom
fuse
lysosom
recycl
macromolecul
process
also
trigger
gener
amino
acid
nucleotid
fatti
acid
condit
nutrient
depriv
type
stress
also
trigger
autophagi
genom
stress
http
receiv
march
receiv
revis
form
april
accept
april
endoplasm
reticulum
stress
intracellular
infect
exposur
drug
previous
observ
certain
chemotherapeut
agent
ultralow
concentr
modul
signal
pathway
induc
cytokin
without
induc
apoptosi
treatment
colorect
cancer
cell
nontox
concentr
paclitaxel
alter
express
sever
gene
especi
respons
synthesi
heat
shock
protein
compon
antigen
process
machineri
apm
tumorassoci
antigen
increas
immunogen
tumor
cell
induc
drug
exposur
depend
onset
socal
immunogen
cell
death
increas
express
danger
signal
eg
dangerassoci
molecular
pattern
damp
calreticulin
heat
shock
protein
atp
high
mobil
group
box
consist
notion
also
observ
expos
cell
nontox
concentr
paclitaxel
doxorubicin
caus
transcript
alter
sever
gene
associ
express
tumor
antigen
addit
dendrit
cell
dc
sensit
lysat
cell
previous
treat
low
concentr
paclitaxel
induc
cytotox
lymphocyt
ctl
higher
lytic
potenti
dc
sensit
untreat
tumor
cell
recent
combin
antineoplast
agent
autophagi
blocker
therapeut
approach
treat
cancer
patient
propos
expos
human
colorect
cancer
cell
enhanc
autophagi
consider
portion
cell
exposur
cell
antimalari
drug
chloroquin
cq
hydroxychloroquin
mefloquin
quinolon
reduc
autophagi
increas
suscept
cell
chemotherapi
quinolon
function
weak
base
passiv
diffus
lysosom
proton
prevent
leav
vesicl
presenc
increas
lysosom
ph
interrupt
function
prevent
end
autophagi
antiinflammatori
drug
quinolon
use
treat
autoimmun
diseas
current
number
clinic
trial
experiment
studi
focus
feasibl
use
cq
hydroxychloroquin
addit
combin
cq
antineoplast
drug
enhanc
clinic
respons
patient
breast
kidney
cancer
show
synergist
effect
activ
mtor
mammalian
target
rapamycin
inhibit
autophagi
thu
increas
tumor
cell
death
studi
induct
autophagi
tumor
cell
treat
ultralow
dose
chemotherapeut
agent
avail
littl
known
effect
phenomenon
immunogen
tumor
cell
furthermor
report
effect
use
cq
combin
drug
function
immunocompet
cell
lymphocyt
dc
present
studi
test
hypothesi
applic
cq
combin
low
concentr
block
autophagi
tumor
cell
promot
dc
matur
increas
abil
enhanc
lymphocyt
cytotox
granul
express
found
expos
cell
combin
induc
transcript
chang
dc
treat
lysat
show
improv
abil
stimul
prolifer
allogen
cell
enhanc
gener
cytotox
cell
result
lead
us
conclud
antigen
transcript
chang
induc
tumor
cell
combin
cq
low
concentr
use
basi
develop
better
dcbase
antitumor
reactiv
cell
human
colon
cancer
cell
line
authent
dna
str
profil
use
geneprint
commerci
system
promega
madison
wi
usa
viral
carcinogenesi
cancer
biolog
research
group
institut
biotechnolog
ibtec
sao
paulo
state
univers
unesp
cell
authent
mycoplasmafre
cultur
cm
cultur
bottl
medium
gibco
supplement
fb
mm
lglutamin
mm
sodium
pyruv
mm
nonessenti
amino
acid
mm
hepe
antibioticsantimycot
solut
life
technolog
cell
cultur
co
atmospher
h
cultur
cell
treat
cq
h
minimum
effect
concentr
eurofarma
ad
cell
cultur
h
cell
detach
trypsin
wash
subsequ
analysi
cryopreserv
prepar
cell
lysat
cq
concentr
incub
time
previous
determin
mttbase
cytotox
assay
cell
plate
flatbottom
cultur
plate
incub
variabl
concentr
cq
increas
optic
densiti
due
formazan
reduct
read
spectrophotomet
evalu
toxic
effect
drug
concentr
concentr
cell
adjust
cellsml
cultur
overnight
plate
cell
treat
cq
overnight
follow
exposur
h
posit
control
cell
death
cell
heat
min
cell
detach
trypsin
centrifug
rpm
min
pellet
suspend
cold
pb
centrifug
rpm
sec
cell
pellet
resuspend
annexin
buffer
solut
incub
annexin
v
room
temperatur
protect
light
incub
annexin
buffer
ad
final
cell
stain
assess
viabil
analyz
flow
cytometri
cryopreserv
aliquot
thaw
water
bath
min
quickli
refrozen
liquid
nitrogen
min
freezethaw
cycl
process
repeat
five
time
sampl
centrifug
rpm
min
supernat
treat
proteas
inhibitor
halt
proteas
inhibitor
cocktail
thermofish
follow
storag
total
protein
quantifi
use
thermofish
bca
protein
assay
kit
sampl
aliquot
protein
store
briefli
cell
lysat
protein
deriv
four
treatment
group
wt
cq
cq
dilut
gel
electrophoresi
sampl
buffer
heat
min
protein
separ
polyacrylamid
gel
transfer
polyvinyliden
difluorid
membran
nonspecif
bind
protein
block
incub
membran
lowfat
milk
pbstween
buffer
h
room
temperatur
membran
subsequ
incub
overnight
antigenspecif
primari
antibodi
autophagi
marker
cell
signal
technolog
mbl
intern
corp
secondari
antirabbit
sigma
antimous
sigma
antibodi
appli
respect
gapdh
sigma
use
housekeep
gene
membran
wash
pbstween
buffer
min
develop
enhanc
chemoluminesc
immunoreact
reagent
read
uvitec
cambridg
photodocument
system
approxim
cell
cultur
overnight
cultur
plate
treat
cq
accord
abovement
protocol
incub
cell
monolay
trypsin
collect
cell
centrifug
min
rpm
sampl
fix
ml
karnovski
solut
postfix
osmium
tetroxid
phosphat
buffer
ph
incub
uranyl
acet
aqueou
solut
dehydr
gradient
seri
aceton
solut
embed
araldit
glue
ultrafin
section
nm
contrast
satur
uranyl
acet
lead
citrat
solut
observ
use
tecnai
spirit
fei
compani
electron
microscop
kv
dc
differenti
vitro
peripher
blood
adher
mononuclear
cell
pbmc
six
healthi
donor
pbmc
obtain
centrifug
ficollisopaqu
gradient
suspend
aimv
cultur
medium
invitrogen
seed
cultur
plate
per
well
incub
h
nonadher
cell
remov
adher
monocyt
cultur
complet
cultur
medium
contain
ngml
recombin
human
gmcsf
peprotech
day
treat
lysat
per
dc
kept
cultur
addit
h
immatur
dc
submit
seven
differ
cultur
condit
dc
untreat
immatur
dc
wt
dc
expos
lysat
untreat
cell
cq
dc
expos
lysat
cell
pretreat
cq
dc
expos
lysat
cell
pretreat
cq
dc
expos
lysat
cell
pretreat
cq
procedur
involv
normal
transform
human
cell
approv
ethic
committe
botucatu
school
medicin
unesp
cep
lysateexpos
control
dc
incub
fluoresc
monoclon
antibodi
min
wash
pb
contain
bovin
serum
albumin
bsa
sodium
azid
dc
incub
label
antibodi
hladrp
bd
bioscienc
min
wash
pbsbsa
cell
suspend
pbsbsa
sampl
read
facscanto
ii
cytomet
bectondickinson
analyz
use
flowjo
version
function
activ
dc
first
evalu
abil
stimul
prolifer
normal
allogen
lymphocyt
dc
six
differ
donor
cocultur
allogen
lymphocyt
previous
mark
carboxyfluorescein
succinyl
ester
cfse
flatbottom
plate
dc
lymphocyt
ratio
cell
harvest
five
day
later
lymphocyt
prolifer
analyz
flow
cytometri
base
dilut
cfse
replic
cell
also
analyz
express
cell
use
bd
pharmingen
supernat
mlr
assay
collect
preserv
sampl
analyz
vitro
synthesi
use
elisa
kit
accord
manufactur
instruct
r
system
gener
specif
antitumor
cell
dc
cocultur
autolog
lymphocyterich
suspens
dc
lymphocyt
ratio
complet
cultur
medium
supplement
ngml
iuml
cultur
puls
everi
two
day
day
day
lymphocyt
harvest
evalu
cytotox
activ
target
cell
lymphocytotox
assay
perform
ad
vitrogener
lymphocyt
monolay
cell
differ
effector
target
ratio
ad
cocultur
incub
h
atmospher
contain
co
cell
harvest
wash
bsa
pb
treat
cytofixcytoperm
kit
bd
pharmingen
final
cell
label
antiperforinalexa
antigranzymep
antibodi
analyz
flow
cytometri
investig
treatment
combin
cq
chang
tumor
cell
gene
express
perform
transcript
analysi
cell
total
rna
extract
use
qiagen
rneasi
plu
micro
kit
rna
quantifi
use
rna
hs
assay
kit
invitrogen
system
qualiti
rna
analyz
use
agil
rna
chip
bioanalyz
system
sampl
rna
integr
number
higher
optim
qualiti
process
indic
step
sure
select
strandspecif
rna
librari
prepar
kit
follow
dsdna
librari
treatment
group
adapt
index
analyz
illumina
miseq
platform
obtain
data
read
assembl
base
sequenc
transcript
interest
use
clc
genom
workbench
program
effect
treatment
gene
express
evalu
compar
fold
chang
rna
express
sampl
untreat
control
homogen
varianc
access
bartlett
test
data
analyz
analysi
varianc
anova
follow
tukeykram
test
multipl
comparison
differ
consid
signific
error
probabl
less
equal
p
first
verifi
whether
work
concentr
cq
abl
block
autophagi
protein
extract
untreat
tumor
cell
wt
cell
treat
either
chloroquin
treat
combin
drug
cq
analyz
western
blot
evalu
accumul
autophag
marker
observ
slightli
increas
express
treat
cq
alon
combin
cq
result
higher
express
interestingli
treatment
alon
induc
slight
increas
express
indic
induct
autophagi
confirm
lower
intens
group
fig
reinforc
cytometr
result
induct
inhibit
autophagi
induct
apoptosi
use
transmiss
electron
microscopi
analyz
cell
differ
treatment
cell
treat
show
doublemembran
vesicl
autophagosom
singlemembran
vesicl
contain
degrad
materi
autophagolysosom
cytoplasm
fig
contrast
control
cell
show
small
number
autophagosom
contain
floccul
degrad
materi
addit
contain
mitochondria
rough
endoplasm
reticulum
cistern
fig
cq
combin
treatment
size
autophagosom
appear
increas
within
cytoplasm
vesicl
exhibit
differ
filler
content
vesicl
heterogen
electrondens
materi
insid
other
show
myelin
figur
electronluc
degrad
materi
indic
autophagosom
engag
digest
process
process
digest
block
clear
accumul
autophagosom
contain
undigest
organel
demonstr
failur
inhibit
autophagolysosom
format
fig
find
agreement
previou
studi
tabl
show
number
cell
incub
cq
combin
drug
five
independ
assay
cq
alon
discret
effect
cell
growth
reduc
number
cell
approxim
control
cultur
column
refer
independ
assay
cultur
differ
day
combin
cq
strongli
inhibit
cell
growth
cultur
fig
show
earli
apoptosi
annexin
v
predomin
type
cell
death
induc
treatment
alon
fig
increas
four
time
annexin
v
label
compar
control
fig
combin
cq
increas
earli
apoptosi
ten
time
compar
control
fig
around
twice
compar
alon
fig
illustr
effect
lysat
dc
phenotyp
highlight
overal
increas
percentag
cell
express
matur
activ
marker
hladr
percentag
cell
express
marker
increas
wt
group
expos
cq
cell
marker
associ
dc
matur
hladr
increas
wt
control
respect
cell
treat
cq
respect
although
treat
cell
cq
alon
increas
immunogen
effect
dc
effect
intens
seen
drug
combin
given
effect
lysat
matur
activ
dc
healthi
individu
analyz
whether
phenotyp
chang
accompani
chang
dc
function
mlr
assay
use
evalu
effect
lysat
abil
dc
induc
allogen
respons
studi
perform
combin
cq
present
relev
phenotyp
chang
fig
show
prolif
respons
total
lymphocyt
fig
c
show
prolifer
cell
respect
although
exposur
cell
cq
alon
increas
dc
matur
compar
wt
effect
intens
drug
combin
result
show
mark
effect
prolifer
lymphocyt
dc
sensit
lysat
cell
pretreat
cq
lymphocyt
respond
allogen
stimul
show
activ
cell
profil
marker
activ
lymphocyt
checkpoint
ligand
express
tumor
cell
assess
dcstimul
cell
fig
g
indic
lymphocyt
gener
exposur
dc
cq
high
frequenc
express
among
lymphocyt
lymphocyt
respect
contrast
express
regulatori
marker
lower
lymphocyt
especi
cell
cq
shown
fig
dc
expos
lysat
cell
treat
cq
increas
abil
induc
product
via
allogen
lymphocyt
level
increas
pgml
wt
pgml
cq
pgml
cq
convers
fig
show
dc
exposur
lysat
decreas
abil
dcstimul
cell
secret
reduc
level
pgml
wt
pgml
cq
pgml
cq
analysi
cytotox
lymphocyt
restrict
express
perforin
granzym
b
molecul
test
effici
lysatetr
dc
gener
autolog
tumorreact
cell
found
lymphocyt
cultur
dc
expos
lysat
cell
treat
cq
induc
gener
lymphocyt
higher
level
perforin
granzym
b
cultur
control
dc
fig
differ
observ
upon
label
data
shown
better
understand
increas
dc
matur
associ
block
autophagi
evalu
cell
treat
cq
combin
gene
fold
chang
use
identifi
signific
differ
gene
express
among
group
tabl
cqtreat
cell
show
modest
increas
express
autophagi
gene
atg
consider
decreas
gene
relat
tumor
progress
well
decreas
nomin
tumor
antigen
member
cea
famili
treatment
induc
increas
autophagi
gene
contrast
cq
group
observ
intens
decreas
gene
relat
tumor
progress
express
cea
gene
increas
cell
treat
cq
show
increas
express
autophagi
gene
well
increas
gene
cea
famili
unlik
group
express
gene
associ
tumor
progress
decreas
develop
resist
antitumor
agent
one
primari
challeng
modern
cancer
therapi
investig
effect
treat
tumor
cell
combin
cq
concentr
chosen
lowest
concentr
capabl
inhibit
tumor
growth
may
therefor
repres
suitabl
vitro
model
metronom
dose
use
fig
lysat
expos
cq
increas
dc
matur
activ
dc
six
healthi
donor
expos
lysat
cell
previous
treat
minim
effect
concentr
combin
cq
cq
wt
refer
dc
puls
lysat
untreat
cell
ctrl
refer
unstimul
dc
scatter
plot
illustr
percentag
dc
coexpress
marker
hladr
b
c
mean
standard
deviat
six
individu
donor
analyz
anova
p
p
p
clinic
although
cq
previous
appli
combin
sever
antineoplast
agent
studi
use
low
concentr
drug
yet
report
increas
level
current
use
suitabl
marker
effect
autophagi
inhibit
autophagi
block
cq
accumul
bind
ubiquitin
protein
especi
form
part
autophagosom
wall
thu
autophagi
enhanc
degrad
inhibit
autophagi
promot
accumul
well
low
concentr
increas
autophagi
cell
cq
abl
inhibit
process
evidenc
accumul
analysi
express
consist
constitut
autophagi
cell
autophagi
induct
also
confirm
transcriptom
analysi
show
increas
express
autophagyassoci
gene
atg
express
enhanc
appli
combin
cq
increas
express
stress
condit
consist
previou
report
ultrastructur
analysi
reveal
untreat
control
cell
neglig
express
autophagosom
autophagolysosom
treat
cq
show
increas
number
fig
improv
dc
antigenpres
function
induc
lysat
treat
cq
dc
expos
lysat
cocultur
allogen
lymphocyt
day
grow
total
lymphocyt
cell
quantifi
flow
cytometri
cell
b
c
n
p
p
lymphocyt
analyz
separ
express
activ
marker
regulatori
molecul
dg
p
p
mlr
supernat
collect
analyz
secret
h
elisa
p
autophagosom
cytoplasm
cell
treat
show
evid
increas
number
autophagolysosom
contain
degrad
materi
indic
induct
autophagi
complet
process
consist
prior
report
combin
treatment
cq
induc
intens
accumul
cytoplasm
vesicl
sever
stage
especi
autophagosom
contain
undigest
materi
also
found
cell
sign
autophag
apoptot
death
cytoplasm
vacuol
chromatin
rarefact
reduct
heterochromat
group
associ
nuclear
envelop
alter
mitochondri
morpholog
dilat
crista
dilat
nuclear
envelop
also
agre
previou
report
phenomenon
confirm
observ
cq
treatment
strongli
reduc
cell
prolifer
induc
earli
apoptosi
tumor
cell
although
cq
alon
appar
effect
cell
viabil
induc
apoptosi
cancer
cell
inhibit
autophagi
cq
potenti
cytotox
occur
accumul
vesicl
cytoplasm
due
incomplet
autophagi
caus
oxid
stress
lead
cell
death
base
inform
aim
confirm
whether
toxic
low
concentr
would
enhanc
cq
studi
apoptosi
cell
death
result
show
cq
increas
level
earli
apoptosi
even
though
drug
concentr
neglig
effect
appli
alon
analyz
effect
cq
treatment
immunogen
tumor
cell
reveal
dc
exposur
lysat
cell
treat
drug
enhanc
matur
antigenpres
cell
dc
matur
requir
increas
antigenpres
abil
accompani
phenotyp
chang
increas
express
mhc
class
ii
costimulatori
molecul
express
express
essenti
lymphocyt
stimul
addit
matur
marker
modul
immun
respons
stimul
naiv
memori
cell
express
also
enhanc
drug
combin
although
apoptot
cell
death
consid
nonimmunogen
weakli
immunogen
possibl
apoptosi
induc
blockag
autophagi
result
express
danger
signal
eg
damp
usual
express
physiolog
apoptosi
parallel
studi
observ
expos
cell
low
concentr
paclitaxel
induc
express
unpublish
data
present
studi
observ
small
increas
express
irrelev
chang
hmgb
gene
find
indic
enhanc
abil
sensit
dc
mainli
due
increas
express
tumorassoci
gene
cea
famili
ceacam
anoth
studi
found
expos
cell
low
dose
paclitaxel
doxorubicin
increas
express
sever
gene
associ
enhanc
tumor
immunogen
total
rna
extract
colorect
cancer
cell
treat
immunogen
transfect
dc
expos
tumor
cell
drug
paclitaxel
doxorubicin
increas
express
antigen
process
machineri
via
cytosol
rout
tapasin
calnexin
view
reinforc
observ
chemic
stress
trigger
cell
surfac
express
calreticulin
calr
anoth
molecul
promot
antigen
process
tumor
cell
interestingli
calr
move
endoplasm
reticulum
function
apm
compon
cytoplasm
membran
serv
potent
activ
signal
calr
togeth
play
import
role
phenotyp
matur
dc
increas
hladr
express
function
matur
well
enhanc
secret
enhanc
effect
tumor
cell
immunogen
reinforc
demonstr
cell
lysat
function
effect
dc
inde
mix
lymphocyt
reaction
mlr
allow
us
demonstr
phenotyp
chang
observ
dc
accompani
improv
abil
stimul
allogen
lymphocyt
specif
dc
sensit
lysat
fig
vitro
gener
cytotox
lymphocyt
ctl
improv
dc
expos
lysat
previous
treat
cq
mean
fluoresc
intens
mfi
prolifer
cell
four
healthi
donor
individu
effector
target
ratio
lymphocyt
show
higher
express
level
cytotox
marker
perforin
mfi
ratio
cq
wt
p
granzym
b
mfi
ratio
cq
wt
p
mfi
ratio
cq
wt
p
compar
wt
control
group
cell
treat
cq
promot
enhanc
prolifer
lymphocyt
mlr
intens
prolif
effect
lymphocyt
also
agreement
abil
interact
hladr
molecul
express
dc
furthermor
increas
prolifer
lymphocyt
suggest
gener
cytotox
lymphocyt
specif
tumor
cell
sinc
prolifer
stimul
dc
sensit
lysat
aim
confirm
combin
cq
stimul
prolifer
lymphocyt
perform
ctl
assay
unlik
mlr
test
abil
dc
stimul
prolifer
autolog
lymphocyt
target
tumor
cell
main
difficulti
evalu
direct
cytotox
ctl
target
cell
cell
adher
avail
assay
purpos
work
well
cell
suspens
reliabl
adher
cell
type
chemiluminescencebas
assay
unabl
acquir
appropri
kit
therefor
decid
evalu
express
perforin
granzym
b
ctl
challeng
tumor
target
cell
follow
methodolog
propos
bett
et
al
protein
consid
function
marker
cell
cytotox
capac
perforin
polymer
perfor
target
cell
membran
granzym
b
induc
apoptosi
expect
found
increas
express
ie
increas
mean
fluoresc
intens
mfi
perforin
granzym
b
popul
induc
dc
sensit
cq
lysat
also
observ
lymphocyt
gener
respons
sensit
dc
express
higher
level
earli
antigen
associ
effect
stimul
lymphocyt
antigenpres
cell
consist
lymphocyt
stimul
dc
expos
cq
lysat
induc
earlier
potent
cell
activ
find
also
indic
select
activ
cell
sinc
percentag
cell
increas
subpopul
accordingli
treatment
result
reduc
gener
cell
among
lymphocyt
member
famili
primari
function
limit
cluster
tcr
costimulatori
molecul
within
immunolog
synaps
express
increas
cell
patient
pancreat
cancer
lung
cancer
variou
leukemia
lymphoma
therefor
express
cell
express
tumor
cell
constitut
tumor
escap
mechan
observ
reduc
express
expand
lymphocyt
cocultur
dc
aspect
particularli
interest
signal
associ
among
main
checkpoint
blockad
antitumor
respons
henc
addit
antibodi
antibodi
mainstay
modern
antitumor
immunotherapi
lymphocyt
cultur
dc
sensit
drugexpos
tumor
cell
produc
higher
amount
control
show
decreas
product
naiv
lymphocyt
differenti
specif
effector
cell
differ
function
attribut
part
pattern
cytokin
produc
cell
differenti
cell
releas
stimul
gener
cell
way
cell
involv
develop
antitumor
immun
respons
interferon
also
recruit
monocyt
induc
differenti
lymphocyt
lymphocyt
dcinhibit
cytokin
secret
treg
inhibit
antigen
present
decreas
express
mhc
ii
costimulatori
molecul
thu
dc
combin
treatment
promot
preferenti
activ
lymphocyt
littl
treg
stimul
analysi
cytokin
tnf
would
use
provid
clearer
view
regard
differ
treatment
affect
modul
cell
subset
quantif
cytokin
consid
futur
studi
final
evid
combin
cq
modul
tumor
cell
biolog
correspond
lysat
reinforc
increas
express
gene
tumorassoci
cea
famili
ceacam
previous
report
decreas
express
gene
associ
tumor
progress
taken
togeth
result
indic
block
autophagi
chloroquin
increas
abil
tumor
cell
matur
dc
induc
antitumor
respons
addit
result
confirm
clinic
applic
protocol
improv
vitro
stimul
dc
well
use
combin
antiautophag
agent
convent
chemotherapeut
agent
treatment
patient
colorect
cancer
data
avail
statement
data
support
find
studi
avail
correspond
author
upon
reason
request
